PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient

Onkologie

Volumn 33, Issue 1-2, 2010, Pages 57-59

  Gasent Blesa, Joan M ^a   Alberola Candel, Vicente ^b  

^a Hospital de Denia   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Fulvestrant; Prostate cancer; PSA control

Indexed keywords

BICALUTAMIDE; DOCETAXEL; FULVESTRANT; GOSERELIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CASE REPORT; DRUG DOSE INCREASE; HORMONE RESISTANCE; HUMAN; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PROSTATE CANCER; TREATMENT OUTCOME;

ACETATES; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMPASSIONATE USE TRIALS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; ESTRADIOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETREATMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 77249142480     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264612     Document Type: Article

References (18)

1. Taplin ME, Ho SM: Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab 2001;86:3467-3477.
2. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-750.
3. Nuttall ME, Pendrak I, Emery JG, Nadeau DP, Fisher PW, Nicholson TA, Zhu Y, Suva LJ, Kingsbury WD, Gowen M: Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents. Cancer Chemother Pharmacol 2001;47:437-443.
4. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG: Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990;87: 6883-6887.
5. Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89:4037-4041.
6. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-3403.
7. Ho SM: Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91:491-503.
8. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM: Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001;159:79-92.
9. Lau KM, LaSpina M, Long J, Ho SM: Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-3182.
10. Mobley JA, L'Esperance JO, Wu M, Friel CJ, Hanson RH, Ho SM: The novel estrogen 17alpha-20Z-21-[(4-amino)phenyl]-19-norpregna-1.3.5(10),20-tetraene-3. 17 beta-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro. Mol Cancer Ther 2004;3:587-595.
11. Culig Z, Bartsch G: Androgen axis in prostate cancer J Cell Biochem 2006;99:373-381.
12. Santos AF, Huang H, Tindall DJ: The androgen receptor: a potential target for therapy of prostate cancer. Steroids 2004;69:79-85.
13. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley W: Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459-476.
14. Rumi S. Bhattacharyya R, Aruna V. Krishnan A V, Swami S, Feldman D: Fulvestrant (ICI 182,780) down-regulates androgenreceptor expression and diminishes androgenicresponses in LNCaP human prostate cancer cells. Mol Cancer Ther 2006;5: 1539-1549.
15. Chadha MK, Ashraf U, Lawrence D: Phase II study of fulvestrant (Faslodex®) in castration resistant prostate cancer. Prostate 2008;68:1461-1466.
16. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M: Comparison of the short-term biological effects of 7alpha-[9-(4.4.5.5.5-pentafluoropentylsulfinyl) -nonyl]estra-1.3.5,(10)-triene-3.17 beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-6746.
17. Gutteridge E, Robertson JFR, Cheung KL, Pinder S, Ellis IO, Wakeling AE: Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer - final results. Breast Cancer Res Treat 2004;88 (suppl 1):S177.
18. Tannock IF, de Wit R, William D, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEJM 2004;351: 1502-1512.